DarwinHealth Publishes Results of Novel, Viral Checkpoint-based Technology for Predicting Drugs that Inhibit SARS-CoV-2 Replication: Global Collaboration Highlights Generalizability of Reported ViroTreat Model for Host Cell-Directed Antiviral Drug Discovery,...
NEW YORK, July 19, 2022 /PRNewswire/ -- DarwinHealth, Inc., a New York-based biotechnology and cancer drug discovery company announces the July 19, 2022 online publication in Communications Biology (a Nature Portfolio peer-reviewed journal) of a foundational paper focused on new approaches to antiviral drug discovery, "A model for network-based identification and pharmacological targeting...
World Brain Day 2022 Will Feature Leading Experts to Promote Brain Health
LONDON, July 20, 2022 /PRNewswire/ -- July 22 is devoted to Brain Health for All for World Brain Day (WBD). This year, in a free webinar, the World Federation of Neurology (WFN) is featuring leading experts from regional and global organizations who are prioritizing brain health, including the World Health Organization (WHO). In honor of World Brain Day...
Brii Bio Announces Strategic Partnership with China Resources Pharmaceutical Commercial Group to Advance the Commercialization of Long-acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China The amubarvimab/romlusevimab combination is the first locally-discovered and approved SARS-CoV-2 target-specific treatment in China, evaluated through a randomized, double-blind, placebo-controlled trial The amubarvimab/romlusevimab combination was commercially launched in China on July 7, 2022 DURHAM, N.C. and BEIJING,...
llumina Among First in the World to Receive Approval of Science-Based Net-Zero Target
The Science Based Targets initiative has validated Illumina's targets to reach Net-Zero greenhouse gas emissions by 2050 SINGAPORE, July 19, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today it is among the first group of companies worldwide to receive approval of its net-zero targets by the Science Based Targets initiative...
Significant Glycemic Control and Weight Loss: Innovent Announces Phase 2 Study of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Met Primary Endpoint
SAN FRANCISCO and SUZHOU, China, July 19, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announces that the primary endpoint was met in a multi-center, randomized, double-blind, placebo and dulaglutide-controlled phase 2 study of...
USAID Announces $200 Million Commitment to Tackle Child Wasting, the Largest Single Investment in Malnutrition Treatment in History
With co-investment from philanthropist Sir Chris Hohn, the CRI Foundation, the Eleanor Crook Foundation, and The ELMA Relief Foundation, this monumental commitment will drive more than a 50% increase in the number of severely malnourished children who receive treatment with Ready-to-use Therapeutic Food (RUTF), a lifesaving, nutrient-dense, peanut-based therapeutic food. WASHINGTON, July 19, 2022 /PRNewswire/ -- Today, USAID Administrator...
SHL Medical announces plans for a new manufacturing site in the US
NORTH CHARLESTON, S.C., July 18, 2022 /PRNewswire/ -- SHL Medical (hereinafter referred to as "SHL") has revealed plans for a new manufacturing site in the US, in response to the growing market demand for its autoinjector product portfolio. The decision stems from SHL's strategic assessments in extending its production to North America. SHL Medical announces new autoinjector manufacturing...
China Pharma Announced the Submission of a Plan of Compliance to NYSE American
HAIKOU, China, July 18, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that on July 15, 2022, the Company submitted a plan of compliance to NYSE American LLC ("NYSE American" or the "Exchange") to address the deficiency in the Company's stockholders' equity as pointed...
I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022
GAITHERSBURG, Md. and SHANGHAI, July 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that an abstract reporting the latest clinical data from a Phase 2 study of lemzoparlimab (also known as TJC4) in combination with azacitidine...
OliPass Moves Forward to Second Stage of Phase 2a Trial for Pain Killer OLP-1002
SEOUL, South Korea, July 18, 2022 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced to move forward to the second stage of the Phase 2a trial in Australia in osteoarthritis (OA) patients for pain killer OLP-1002, an SCN9A antisense PNA selectively inhibiting the expression of Nav1.7 sodium ion channel. The Phase...
